Company Overview of Fresenius Kabi Pharmaceuticals Holding, Inc.
Fresenius Kabi Pharmaceuticals Holding, Inc. develops, manufactures, and markets injectable pharmaceutical products in North America. Its oncology products include Carboplatin for the advanced ovarian carcinoma; Doxorubicin for breast cancer; Fludarabine for B-cell chronic lymphocytic leukemia; Fluorouracil to inhibit the growth of cancer cells; Ifosfamide to treat germ cell testicular cancer; Irinotecan for cancer of the large intestine and rectum; Mesna for the side effects related to chemotherapy drugs; Paclitaxel Injection for the carcinoma of the ovary and non-small cell lung cancer; Cisplatin Injection for metastatic testicular tumors; Oxaliplatin; and Topotecan for Injection for small...
Bad Homburg vdh
Bad Homburg, 61352
Founded in 1996
Key Executives for Fresenius Kabi Pharmaceuticals Holding, Inc.
Chief Executive Officer, President and Director
Chief Operating Officer and Executive Vice President
Chief Scientific Officer and Executive Vice President
Senior Vice President of Manufacturing
Executive Vice President and General Counsel
Compensation as of Fiscal Year 2016.
Fresenius Kabi Pharmaceuticals Holding, Inc. Key Developments
Fresenius Kabi Introduces Cisatracurium Besylate Injection
Aug 12 15
Fresenius Kabi has introduced its Cisatracurium Besylate Injection, a new specialty injectable product, in three presentations in the United States. The product is the generic equivalent of Nimbex and was approved by the US Food and Drug Administration. It is an intermediate-onset and intermediate-duration neuromuscular blocker for inpatient and outpatient use as an adjunct to general anaesthesia, to facilitate tracheal intubation. It is offered in three presentations: a 10 mg per 5 mL single use vial, a 20 mg per 10 mL multiple dose vial and a 200 mg per 20 mL single use vial. With the introduction of Cisatracurium, Fresenius Kabi delivers clinicians another choice in neuromuscular blockers while fostering commitment to provide customers access to one of the most comprehensive anaesthesia portfolios in the US.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries